Biopharma companies needed a bit more effort to make this year’s list of top 10 job cutters compared with a year ago—nearly 50% more effort.
This year’s top 10 disclosed plans to eliminate a total of more than 28,000 jobs in 2013, up nearly 50% from the 18,910 jobs eliminated by the top 10 job cutters of 2012. Big pharma continues to slash their workforces—especially in high-paying positions—from research to administrative, and from manufacturing to sales.
Some of the cuts reflect responses to patent-cliff losses as protection expires for blockbusters. Other layoffs reflect the usual pruning of duplicate jobs that arises following mergers and acquisitions. But many of the job reductions augur further cutbacks in manufacturing in the U.S. and Europe, as companies seek the same savings from outsourcing production to Asia that numerous other industries have reaped over much of the past generation.
Below is a list of biopharma companies ranked by the 10 largest numbers of job reductions disclosed in 2013. Each company is listed by name, the number of disclosed layoffs, details on the layoffs if any, the justification furnished by the company for the cuts, and the size of the company’s total workforce.